Lung Carcinoma in Situ

Categories: Respiratory diseases, Cancer diseases, Genetic diseases

Aliases & Classifications for Lung Carcinoma in Situ

MalaCards integrated aliases for Lung Carcinoma in Situ:

Name: Lung Carcinoma in Situ 12 14


External Ids:

Disease Ontology 12 DOID:8800
ICD10 33 D02.2
ICD9CM 35 231.2
SNOMED-CT 64 189262006 189268005
UMLS 69 C0154071

Summaries for Lung Carcinoma in Situ

MalaCards based summary : Lung Carcinoma in Situ An important gene associated with Lung Carcinoma in Situ is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A). The drugs Pemetrexed and Trastuzumab have been mentioned in the context of this disorder. Affiliated tissues include lung, breast and testes.

Related Diseases for Lung Carcinoma in Situ

Symptoms & Phenotypes for Lung Carcinoma in Situ

Drugs & Therapeutics for Lung Carcinoma in Situ

Drugs for Lung Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
Trastuzumab Approved, Investigational Phase 3 180288-69-1 9903
Terlipressin Approved, Investigational Phase 3 14636-12-5 72081
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265
Erlotinib Hydrochloride Phase 3,Phase 2,Phase 1 183319-69-9 176871
8 Folic Acid Antagonists Phase 3
9 Nucleic Acid Synthesis Inhibitors Phase 3
10 Vitamin B Complex Phase 3
11 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
12 Immunoglobulins Phase 3,Phase 2
13 Antibodies Phase 3,Phase 2
14 Antibodies, Monoclonal Phase 3,Phase 2
15 Central Nervous System Depressants Phase 3
16 Natriuretic Agents Phase 3
17 Coagulants Phase 3
18 Hemostatics Phase 3
19 Anesthetics Phase 3
20 Vasoconstrictor Agents Phase 3
21 Antihypertensive Agents Phase 3
22 Lypressin Phase 3
23 Folate Nutraceutical Phase 3
24 Vitamin B9 Nutraceutical Phase 3
Tamoxifen Approved Phase 2 10540-29-1 2733526
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
nivolumab Approved Phase 2 946414-94-4
29 Analgesics Phase 2
30 Selective Estrogen Receptor Modulators Phase 2
31 Cyclooxygenase 2 Inhibitors Phase 2
32 Cyclooxygenase Inhibitors Phase 2
33 Analgesics, Non-Narcotic Phase 2
34 Hormone Antagonists Phase 2
35 Hormones Phase 2
36 Vaccines Phase 1, Phase 2
37 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
38 Peripheral Nervous System Agents Phase 2
39 Pharmaceutical Solutions Phase 2,Phase 1
40 Estrogen Antagonists Phase 2
41 Estrogen Receptor Modulators Phase 2
42 Estrogens Phase 2
43 Anti-Inflammatory Agents Phase 2
44 Anti-Inflammatory Agents, Non-Steroidal Phase 2
45 Bone Density Conservation Agents Phase 2
46 Antirheumatic Agents Phase 2
47 Antineoplastic Agents, Hormonal Phase 2
48 Acyclovir Phase 2
49 valacyclovir Phase 2
50 Anti-Infective Agents Phase 2

Interventional clinical trials:

(show all 48)

id Name Status NCT ID Phase Drugs
1 Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00989690 Phase 3 docetaxel;erlotinib hydrochloride;pemetrexed disodium
2 Study of Ablation for the Pulmonary Focal Pure Ground Glass Opacity (pGGO) Unknown status NCT01429649 Phase 3
3 Comparing Diagnostic Yield Between R-EBUS Guided Cryo Biopsy Vs. CT Guided Biopsy for PPL Recruiting NCT02395939 Phase 3
4 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
5 Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
6 Interest of in Situ Terlipressin Administration Before the Realisation of Bronchial Biopsy Not yet recruiting NCT02970175 Phase 3 Terlipressin administration
7 Erlotinib Hydrochloride With or Without Celecoxib in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer Completed NCT00499655 Phase 2 erlotinib hydrochloride;celecoxib
8 ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia Completed NCT00522197 Phase 2
9 A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification Completed NCT02435121 Phase 2 SAR125844
10 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Completed NCT00764322 Phase 2 tamoxifen citrate
11 In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation Completed NCT00861107 Phase 1, Phase 2
12 Trial of Stereotactic Body Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma Recruiting NCT02831933 Phase 2 Valacyclovir;nivolumab
13 SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC Recruiting NCT03004183 Phase 2 Valacyclovir;Pembrolizumab
14 Study of Pembrolizumab (MK-3475) for High Risk Oral Intra-Epithelial Neoplasias Recruiting NCT02882282 Phase 2 Pembrolizumab
15 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer Active, not recruiting NCT01556243 Phase 2
16 LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer Terminated NCT00260598 Phase 2
17 Multi-catheter High Dose Rate (HDR) Breast Brachytherapy Terminated NCT00214149 Phase 2
18 Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer Withdrawn NCT01065441 Phase 1, Phase 2
19 Photodynamic Therapy Using HPPH in Treating Patients With Stage 0 Non-Small Cell Lung Cancer Completed NCT00526461 Phase 1 HPPH
20 Photodynamic Therapy in Treating Patients With Lung Cancer Completed NCT01668823 Phase 1 HPPH;photodynamic therapy
21 A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer Completed NCT01121575 Phase 1 PF-02341066;PF-00299804;PF-02341066;PF-00299804
22 Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor Completed NCT02086721 Phase 1 L19-IL2
23 Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer Recruiting NCT02570815 Phase 1 indocyanine green
24 Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer Recruiting NCT02808143 Phase 1
25 Visualising c-MET and Activated Neutrophils in Lung Cancer Not yet recruiting NCT02676050 Phase 1
26 Pemetrexed in Advanced Non-small Cell Lung Cancer Unknown status NCT01193959
27 A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response Unknown status NCT01523340
28 Clinical Relevance of ROS (V-ros UR2 Sarcoma Virus Oncogene Homolog) Aberrations in Solid Tumours Unknown status NCT01596374
29 Comparison of qPCR to IHC and FISH for Detection of ALK Fusion Mutations in FFPE Tissue From NSCLC Patients Completed NCT02010047
30 Detection of Chromosomal Aberrations in Non-small Cell Lung Cancer (NSCLC) Using Fluorescent in Situ Hybridization (FISH) (ALK Test) Completed NCT01620853
31 Non Small Cell Lung Cancer Evaluation According to Pre-determined Drug-targeting Tumor Markers Completed NCT01141686
32 Identifying Biomarkers for Lung Cancer Using Tissue Samples From Patients With Lung Cancer and From Healthy Participants Completed NCT00899028
33 S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer Completed NCT00450281
34 Construction and Use of Lung Tumor Microarray for the Analysis of Gene Expression in Lung Cancer Completed NCT00340847
35 Radiation Therapy Planning Techniques in Reducing Damage to Normal Tissue in Women Undergoing Breast-Conserving Surgery for Ductal Carcinoma of the Breast Completed NCT00602628
36 Comparison of Pleural Drainage Systems on Reducing Pleural Effusion Formation Following Lung Resection Completed NCT01776372
37 UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer Completed NCT00900094
38 Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) Recruiting NCT02194738
39 A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing Recruiting NCT02705404
40 Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma Recruiting NCT02951897 chemotherapy(pemetrexed+CISPLATIN)
41 S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) Recruiting NCT02728596
42 Treatment of Multifocal Lung Adenocarcinoma Recruiting NCT01946100
43 Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease Active, not recruiting NCT00784329
44 Study of the Expression of Met Receptor Fragments in Non Small Cell Lung Cancers Active, not recruiting NCT01647867
45 Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer Active, not recruiting NCT01706432
46 Staging Accuracy of a Selective Lymphadenectomy Strategy in Early Stage NSCLC Not yet recruiting NCT03216551
47 Comparison Between Wedge Resection and Segmentectomy for Ground Glass Opacity- Dominant Stage IA NSCLC Not yet recruiting NCT02718365
48 Laboratory Study Using Samples From Patients With Non-Small Cell Lung Cancer Treated on Clinical Trial CASE-2507 Withdrawn NCT00907699

Search NIH Clinical Center for Lung Carcinoma in Situ

Genetic Tests for Lung Carcinoma in Situ

Anatomical Context for Lung Carcinoma in Situ

MalaCards organs/tissues related to Lung Carcinoma in Situ:

Lung, Breast, Testes, Neutrophil, Liver, Bone

Publications for Lung Carcinoma in Situ

Variations for Lung Carcinoma in Situ

Cosmic variations for Lung Carcinoma in Situ:

9 (show top 50) (show all 78)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM95548 XRCC6 lung,NS,carcinoma,undifferentiated carcinoma c.1159A>C p.I387L 4
2 COSM95544 XRCC1 lung,NS,carcinoma,undifferentiated carcinoma c.1207A>G p.M403V 4
3 COSM95531 WNT8A lung,NS,carcinoma,undifferentiated carcinoma c.368G>C p.G123A 4
4 COSM95521 WNT10B lung,NS,carcinoma,undifferentiated carcinoma c.1006A>C p.K336Q 4
5 COSM95485 USP5 lung,NS,carcinoma,undifferentiated carcinoma c.755C>T p.T252I 4
6 COSM95476 USP38 lung,NS,carcinoma,undifferentiated carcinoma c.994G>C p.A332P 4
7 COSM96265 USP32 lung,NS,carcinoma,undifferentiated carcinoma c.192T>A p.I64I 4
8 COSM94158 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.2691A>T p.Q897H 4
9 COSM94159 UBR5 lung,NS,carcinoma,undifferentiated carcinoma c.1555A>G p.S519G 4
10 COSM95420 TYK2 lung,NS,carcinoma,undifferentiated carcinoma c.3560G>T p.C1187F 4
11 COSM95390 TRAF5 lung,NS,carcinoma,undifferentiated carcinoma c.302G>C p.R101T 4
12 COSM10768 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.535C>T p.H179Y 4
13 COSM10742 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.578A>G p.H193R 4
14 COSM43750 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.811G>T p.E271* 4
15 COSM43753 TP53 lung,NS,carcinoma,undifferentiated carcinoma c.560-1G>A p.? 4
16 COSM95367 TLR5 lung,NS,carcinoma,undifferentiated carcinoma c.1A>G p.M1V 4
17 COSM95359 TLR4 lung,NS,carcinoma,undifferentiated carcinoma c.337C>A p.P113T 4
18 COSM95356 TLR2 lung,NS,carcinoma,undifferentiated carcinoma c.1169A>G p.Q390R 4
19 COSM95347 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.1087C>T p.P363S 4
20 COSM95342 TLN1 lung,NS,carcinoma,undifferentiated carcinoma c.5624C>T p.S1875L 4
21 COSM95340 TLE4 lung,NS,carcinoma,undifferentiated carcinoma c.859A>C p.K287Q 4
22 COSM95334 TIAM1 lung,NS,carcinoma,undifferentiated carcinoma c.3718G>C p.E1240Q 4
23 COSM95292 STK38 lung,NS,carcinoma,undifferentiated carcinoma c.407C>G p.A136G 4
24 COSM95282 STAT1 lung,NS,carcinoma,undifferentiated carcinoma c.2042A>T p.Y681F 4
25 COSM95276 SPRY2 lung,NS,carcinoma,undifferentiated carcinoma c.652T>C p.C218R 4
26 COSM95270 SPOP lung,NS,carcinoma,undifferentiated carcinoma c.570A>C p.L190F 4
27 COSM94327 RNF145 lung,NS,carcinoma,undifferentiated carcinoma c.647G>A p.G216E 4
28 COSM95658 RIN1 lung,NS,carcinoma,undifferentiated carcinoma c.1210C>T p.Q404* 4
29 COSM95187 RICTOR lung,NS,carcinoma,undifferentiated carcinoma c.1711C>A p.H571N 4
30 COSM96136 PLCG1 lung,NS,carcinoma,undifferentiated carcinoma c.3366C>T p.D1122D 4
31 COSM95013 PKHD1 lung,NS,carcinoma,undifferentiated carcinoma c.2753C>A p.P918Q 4
32 COSM94967 PIK3C2A lung,NS,carcinoma,undifferentiated carcinoma c.3240A>T p.E1080D 4
33 COSM94958 PDIA4 lung,NS,carcinoma,undifferentiated carcinoma c.1735G>T p.V579F 4
34 COSM96110 PAX6 lung,NS,carcinoma,undifferentiated carcinoma c.372G>T p.G124G 4
35 COSM94918 PARP1 lung,NS,carcinoma,undifferentiated carcinoma c.790C>G p.L264V 4
36 COSM94897 P2RY1 lung,NS,carcinoma,undifferentiated carcinoma c.238A>G p.M80V 4
37 COSM94878 NTSR1 lung,NS,carcinoma,undifferentiated carcinoma c.808G>T p.A270S 4
38 COSM94867 NRG3 lung,NS,carcinoma,undifferentiated carcinoma c.490G>T p.A164S 4
39 COSM94848 NOTCH2 lung,NS,carcinoma,undifferentiated carcinoma c.5637G>A p.M1879I 4
40 COSM95032 MED1 lung,NS,carcinoma,undifferentiated carcinoma c.2444A>G p.H815R 4
41 COSM94685 MC5R lung,NS,carcinoma,undifferentiated carcinoma c.458T>C p.I153T 4
42 COSM94681 MAX lung,NS,carcinoma,undifferentiated carcinoma c.368A>G p.Y123C 4
43 COSM94657 MAML1 lung,NS,carcinoma,undifferentiated carcinoma c.2605C>A p.Q869K 4
44 COSM94614 LMTK2 lung,NS,carcinoma,undifferentiated carcinoma c.2931C>A p.S977R 4
45 COSM95625 LHCGR lung,NS,carcinoma,undifferentiated carcinoma c.1660C>T p.R554* 4
46 COSM520 KRAS lung,NS,carcinoma,undifferentiated carcinoma c.35G>T p.G12V 4
47 COSM516 KRAS lung,NS,carcinoma,undifferentiated carcinoma c.34G>T p.G12C 4
48 COSM95622 KIF27 lung,NS,carcinoma,undifferentiated carcinoma c.620C>G p.S207* 4
49 COSM94573 KEAP1 lung,NS,carcinoma,undifferentiated carcinoma c.1000T>C p.Y334H 4
50 COSM94797 KAT6B lung,NS,carcinoma,undifferentiated carcinoma c.649A>G p.S217G 4

Expression for Lung Carcinoma in Situ

Search GEO for disease gene expression data for Lung Carcinoma in Situ.

Pathways for Lung Carcinoma in Situ

GO Terms for Lung Carcinoma in Situ

Sources for Lung Carcinoma in Situ

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....